Abstract
AbstractArtemisinin combination therapies (ACTs) are highly effective at treating uncomplicatedPlasmodium falciparummalaria. However, the emergence of a novelpfkelch13R561H mutation in Rwanda, with associated delayed parasite clearance, suggests that drug policy interventions are needed to delay the fixation and slow the spread of this mutation. Using a spatial, stochastic, individual-based model calibrated and validated for the Rwanda’s malaria epidemiology, we evaluate seventeen strategies aimed at minimizing treatment failures and delaying the spread of R561H. The primary measures evaluated are projected treatment failures and R561H allele frequency over three, five, and ten years. Lengthening courses of treatment, deploying multiple first-line therapies, and custom rotation strategies all provide a benefit when compared to the status quo. The best intervention options, five years into the future, result in slower spread of R561H (0.16 allele frequency difference) and absolute treatment failure counts that are 44% lower than projected under the status quo.
Publisher
Cold Spring Harbor Laboratory
Reference43 articles.
1. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
2. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
3. World Health Organization. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010 - 2019) [Internet]. Geneva: World Health Organization; 2020 p. 78. Available from: https://apps.who.int/iris/bitstream/handle/10665/336692/9789240012813-eng.pdf
4. World Health Organization. World Malaria Report 2021 [Internet]. Geneva, Switzerland: World Health Organization; 2021 [cited 2022 Jun 17]. Available from: https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021
5. Artemisinin resistance in Africa: How urgent is the threat?;Med,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献